(Q34826559)

4 August 2017

1 reference

title

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease (English)

1 reference

4 August 2017

1 reference

1 reference

Mark Harries

1

1 reference

4 August 2017

Martin Gore

series ordinal

2

1 reference

4 August 2017

publication date

1 September 2002

1 reference

Lancet Oncology Commission

4 August 2017

published in

1 reference

4 August 2017

volume

3

1 reference

4 August 2017

issue

9

1 reference

4 August 2017

page(s)

537-545

1 reference

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Tumor markers in the management of patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Hexamethylmelamine as a Single Second-Line Agent in Ovarian Cancer: Follow-up Report and Review of the Literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Epirubicin for pretreated advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Phase II trial of epirubicin at standard dose in relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Chlorambucil for platinum-refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Bowel obstruction in patients with ovarian carcinoma: analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Impact of cisplatin multiagent chemotherapy and total parenteral hyperalimentation on bowel obstruction caused by ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Steroid hormone receptors and long term survival in invasive ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900847-1

7 January 2021

10.1016/S1470-2045(02)00847-1

Identifiers

DOI

1 reference

4 August 2017

1 reference